Firm intentionHealthcare20 October 2026

Laboratory Corporation of America to acquire Myriad Genetics, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Laboratory Corporation of America
Target
Myriad Genetics, Inc.
Deal value
Not disclosed
Announced
20 October 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
Not stated
What we know

Laboratory Corporation of America has agreed to acquire Myriad Genetics, Inc. in a transaction structured as an asset sale. Both entities are based in the United States and operate within the healthcare sector. The deal was announced on 20 October 2026. The specific financial terms, including the total deal value and the form of consideration, have not been disclosed. Consequently, no figures regarding the purchase price or currency are available for this transaction. The acquisition represents a significant move within the US healthcare landscape, involving the transfer of specific assets from Myriad Genetics to Laboratory Corporation of America. No completion date has been reported for this agreement. The transaction is currently at the firm intention stage.

Deal timeline

1 update
  1. Firm intention

    Laboratory Corporation of America firm intention to acquire Myriad Genetics, Inc.

    Item 7.01 is a press release announcing the Company’s entry into the Purchase Agreement. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by refer

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

10 November 2026Firm intentionHealthcare

BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.

BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…

Buyer
BioNTech US Inc.
Target
Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
Deal value
USD 205,000,000
Deal type
asset sale

Buyer history

Laboratory Corporation of America

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive